Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

• Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is sharing his experience with ZORYVE® (roflumilast) topical foam, 0.3%, to help others learn more about this chronic inflammatory skin condition
  
  
• ZORYVE foam is a once-daily, steroid-free, topical for seborrheic dermatitis uniquely formulated for use anywhere on the body, including hair-bearing areas
  
  
• Seborrheic dermatitis impacts more than 10 million Americans and is the third most common skin condition affecting Blacks

WESTLAKE VILLAGE, Calif., Feb. 4, 2025 /PRNewswire/ -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a partnership with the iconic professional football player, Odell Beckham Jr. ("OBJ"), to help raise awareness of seborrheic dermatitis ("seb derm") a common, chronic, recurrent inflammatory skin disease that can cause flaking, redness, itching, and discoloration of the skin.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/arcutis/9314051-en-odell-beckham-jr-arcutis-clear-win-for-your-skin-seborrheic-dermatitis-campaign

"My seborrheic dermatitis started to bother me in my 20s when I noticed white flaky skin throughout my beard and at my hairline accompanied by a deep, burning itchy sensation that was extremely uncomfortable," said Odell Beckham Jr., a father, professional football player, and ZORYVE spokesperson. "After trying to figure out the cause for several years, I finally visited my dermatologist who diagnosed me with seb derm and prescribed ZORYVE foam, which works really well for me. Now I want to help others understand the condition, find a treatment option that works for them, and get a clear win for their skin."

Seborrheic dermatitis is a common, chronic, recurrent inflammatory skin disease that affects approximately 10 million Americans and occurs most often on areas of the body with oil-producing (sebaceous) glands, including the scalp, face (especially on and around the nose, eyebrows, and eyelids), ears, upper chest, and back. The path to diagnosis can be challenging, often leading to misdiagnosis, which can delay treatment.

"Seborrheic dermatitis is a common condition that I see frequently in my practice, particularly among Black patients," said Dr. Karan Lal, DO, MS, FAAD, double-board certified dermatologist. "Seb derm is often misunderstood or misdiagnosed, and it can present differently in darker skin tones appearing more purple instead of red, so it is crucial to have a proper diagnosis. The key to managing seborrheic dermatitis effectively is finding the right treatment that works for each individual. ZORYVE is a unique treatment option because it is a steroid-free topical foam that can be used anywhere on the body, including the scalp, face and beard, to help clear skin and reduce itch."

ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. ZORYVE foam provides rapid disease clearance and significant reduction in itch, with nearly 80% of the 458 individuals using ZORYVE achieving clear or almost clear skin at Week 8 in two clinical trials, compared to 53% of the 225 individuals who used a vehicle (a foam not containing the active ingredient). In addition, 63% of the 206 individuals using ZORYVE had significant itch relief at Week 8, compared to 41% of the 98 people using a vehicle, in one of the clinical trials. ZORYVE is a once-daily steroid-free foam and was the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

"We know that beyond the appearance and irritation of physical symptoms, for many people seborrheic dermatitis can cause a decrease in quality of life and may affect emotional well-being, self-esteem, and day-to-day life," said Frank Watanabe, president and chief executive officer of Arcutis. "That's why we're excited to team up with OBJ to encourage people who may be suffering from this condition to speak with their dermatology specialist to see if ZORYVE foam is right for them."

Odell Beckham Jr. adds, "Seb derm is such a common condition but like me, many people may have a hard time trying to figure out what it is and what can be done about it. I want to inspire people not to be embarrassed or discouraged about their condition and instead be empowered to find a dermatologist and work together to find a treatment that works for them."

ZORYVE foam is safe and well tolerated. The most common side effects are common cold, nausea, and headache. For more information on ZORYVE foam including full prescribing information, please visit ZORYVE.com.

About ZORYVE®
ZORYVE (roflumilast) topical foam, 0.3%, is indicated for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. Another formulation of ZORYVE, roflumilast cream, 0.3%, is approved by the FDA for the topical treatment of plaque psoriasis in individuals 6 years of age and older. ZORYVE roflumilast cream, 0.15%, is approved by the FDA for the topical treatment of mild to moderate atopic dermatitis in patients 6 years of age and older. In 2024, ZORYVE cream, 0.15%, was awarded Glamour's Beauty and Wellness award. Both ZORYVE foam and cream are topical formulations of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators. It is an established target in dermatology.

INDICATIONS

ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

Please see full Prescribing Information for ZORYVE foam and full Prescribing Information for ZORYVE cream.

ZORYVE is for topical use only and not for ophthalmic, oral, or intervaginal use.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis' dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential of ZORYVE foam to simplify disease management for care of seborrheic dermatitis; or the potential of real-world use results of ZORYVE foam on individual patients. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the "Risk Factors" section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Arcutis Biotherapeutics, Inc.